Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine

Overview of attention for article published in Frontiers in immunology, January 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 37,422 followers.

RT @FrontImmunol: New Research: Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agra…

11 Jan 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agra…

11 Jan 2022

Reply Repost Favourite

New Research: Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine: Late onset neutropenia (LON) related to rituximab or rituximab plus… https://t.co/mB0PXP

11 Jan 2022

Reply Repost Favourite

RT @GarbineLizeaga: Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis…

10 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.